Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Variable   n (%)
Age, years <70
≥70
24 (44)
30 (56)
Sex Male
Female
42 (78)
12 (22)
Etiology HCV
HBV
Alcohol-related
Unknown
24 (44)
11 (20)
7 (13)
12 (23)
Child-Pugh score, points 5
≥6
33 (61)
21 (39)
TNM staging III
IV
23 (43)
31 (57)
Vascular invasion -
+
40 (74)
14 (26)
Maximum tumor size, mm <50
≥50
33 (61)
21 (39)
Previous therapy Curative
Other
None
35 (65)
14 (26)
5 (9)
Serum alpha fetoprotein, ng/mL <100
≥100
25 (54)
29 (46)
DCP, mAU/mL a <1000
≥1000
27 (52)
25 (48)
Initial dose of sorafenib, mg 200
400
600
800
10 (19)
14 (26)
6 (11)
24 (44)
  1. DCP des-gamma-carboxy prothrombin, HCV hepatitis C virus, HBV hepatitis B virus
  2. aDCP values were not available for two cases